References
- Resolor (prucalopride) Summary of product characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001012/WC500053998.pdf Accessed March 26, 2012
- Frampton JE Prucalopride Drugs 2009 69 17 2463 2476 19911858
- Camilleri M Kerstens R Rykx A Vandeplassche L A placebo-controlled trial of prucalopride for severe chronic constipation N Engl J Med 2008 358 22 2344 2354 18509121
- Tack J van Outryve M Beyens G Kerstens R Vandeplassche L Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives Gut 2009 58 3 357 365 18987031
- Quigley EM Vandeplassche L Kerstens R Ausma J Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation – a 12-week, randomized, double-blind, placebo-controlled study Aliment Pharmacol Ther 2009 29 3 315 328 19035970
- Van de Velde V Ausma J Vandeplassche L Pharmacokinetics of prucalopride (Resolor®) in man Gut 2008 Suppl 2 A282 (abstract)
- Movetis Prucalopride subjects with renal impairment ClinicalTrialsgov [website on the Internet] Bethesda, MD US National Library of Medicine 2012 [updated August 27, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT01674192. NLM identifier: NCT01674192 Accessed September 22, 2012
- European Medicines Agency (EMEA) Note for Guidance on Good Clinical Practice ICH harmonized tripartite guideline, CPMP/ICH/135/95 London EMEA 2002 Available from: http://www.emea.europa.eu/pdfs/human/ich/013595en.pdf Accessed June 11, 2012
- World Medical Association (WMA) WMA Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects Available from: http://www.wma.net/en/30publications/10policies/b3/ Accessed August 12, 2009